-+ 0.00%
-+ 0.00%
-+ 0.00%

Lenz Therapeutics Targets 2027 Operating Expenses of $70-$75 Million, Excluding Stock-Based Compensation

PUBT·11/09/2026 23:51:33
Listen to the news
Lenz Therapeutics Targets 2027 Operating Expenses of $70-$75 Million, Excluding Stock-Based Compensation
  • Lenz Therapeutics targets 2027 operating expenses of $70-$75 million, roughly 50% below prior estimates, excluding stock-based compensation.
  • Sales and marketing will account for approximately 70% of targeted spending, with total staffing of about 40 full-time employees.
  • Third-quarter 2026 revenue reached $2.6 million, up more than 50% sequentially.
  • Cash exceeded $197 million as of Sept. 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.